{"doi":"10.1016/j.jinf.2021.11.020","title":"Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season","abstract":null,"journal":"Journal of Infection","year":2022,"id":595616,"datarank":0.32958368660043297,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.0,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":131235,"name":"Naoki Kawai","orcid":null,"position":1,"is_corresponding":false},{"id":1525235,"name":"Yong Chong","orcid":null,"position":2,"is_corresponding":false},{"id":1525236,"name":"Takuma Bando","orcid":null,"position":3,"is_corresponding":false},{"id":1525238,"name":"Norio Iwaki","orcid":null,"position":4,"is_corresponding":false},{"id":150405,"name":"Seizaburo Kashiwagi","orcid":null,"position":5,"is_corresponding":false},{"id":1525241,"name":"Hideyuki Ikematsu","orcid":null,"position":6,"is_corresponding":false},{"id":195880,"name":"Naoki Tani","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season","abstract":"<h4>Objectives</h4>To investigate the susceptibility of epidemic influenza viruses to neuraminidase inhibitors (NAIs) and the emergence of resistant viruses after treatment, a prospective, observational study was done in the 2019-20 Japanese influenza season.<h4>Methods</h4>Influenza viruses were isolated before and twice after treatment, the first at day 5 and the second at day 10. The 50% inhibitory concentrations (IC<sub>50</sub>s) to oseltamivir, zanamivir, peramivir, and laninamivir were measured and compared with those of 2010-11 to 2018-19 seasons. NA amino acid sequences were analyzed by next generation sequencing (NGS).<h4>Results</h4>The IC<sub>50</sub> geometric means of the NAIs for 128 A(H1N1)pdm09, 2 A(H3N2), and 33 B were comparable to those of the previous seasons. Only 2 (1.6%) A(H1N1)pdm09 with significantly high IC<sub>50</sub> to oseltamivir were found pretreatment. No A(H3N2) or B had resistance. Treatment-emergent oseltamivir resistance was found in 2 among 33 oseltamivir-treated A(H1N1)pdm09, only at the second follow-up. The NGS indicated a rapid increase in the proportion of H275Y to wild type, from 0% to almost 100% between days 5 and 10.<h4>Conclusions</h4>These results suggest the continued effectiveness of these NAIs for epidemic influenza in Japan. Treatment-emergent resistant H275Y A(H1N1)pdm09 viruses were detected after oseltamivir treatment, rapidly replacing the wild type.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34861350","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0163445321005831?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0163445321005831?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":["Antiviral Agents","Cyclopentanes","Drug Resistance, Viral","Humans","Influenza A Virus, H1N1 Subtype","Influenza A Virus, H3N2 Subtype","Influenza, Human","Japan","Neuraminidase","Oseltamivir","Prospective Studies","Seasons"],"mesh_terms":["Humans","Cyclopentanes","Neuraminidase","Antiviral Agents","Prospective Studies","Seasons","Drug Resistance, Viral","Japan","Influenza, Human","Influenza A Virus, H3N2 Subtype","Influenza A Virus, H1N1 Subtype","Oseltamivir"],"keywords":["Resistance","Influenza Virus","Oseltamivir","Inhibitory Concentration 50","neuraminidase inhibitor"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T17:42:40.419231Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}